Evaluation of Utilizing the Distinct Genes as Predictive Biomarkers in Late-Onset Alzheimer's Disease

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by a devastating decline in cognitive activities among all types of dementia, and it severely affects the quality of life. Late-onset AD (LOAD) occurs after the age of 65 years and develops sporadically. Although aging comes first along the main risk factors underlying LOAD, disease-causing susceptibility genes have been associated with disease pathogenesis. In our study, we included the genes PARP1, POLB, HTRA2, SLC1A2, HS1BP3, and DRD3 to be investigated in LOAD patients based on their expression levels. Within this framework, we aimed to determine the possible functions of these genes in the pathophysiology of the disease. We investigated whether the utilization of these genes as biomarkers in the early diagnosis of LOAD may help the treatment scheme to be applied in the clinic. We involved 50 individuals in the study and collected peripheral blood samples from the patients and control groups for molecular genetic analysis. Subsequently, RNA was extracted from the peripheral blood samples, and expression analyzes were performed using qualitative reverse transcription polymerase chain reaction. The results obtained were evaluated by using proper statistical methods. Our results demonstrated that there was no difference between patient and control groups in terms of HTRA2, DRD3, HS1BP3, and POLB genes. The expression levels of the SLC1A2 and PARP1 genes were significantly lower in the patient group compared with the control group. In conclusion, we presume that the PARP1 and SLC1A2 genes can be utilized as molecular biomarkers for LOAD.

Keywords

PARP1 / POLB / HTRA2 / SLC1A2 / HS1BP3 / DRD3

References

[1] D'Argenio V, Sarnataro D. New insights into the molecular bases of familial Alzheimer's disease. J Pers Med 2020; 10(02): 1-14

[2] Rabbito A, Dulewicz M, Kulczyńska-Przybik A, Mroczko B.Biochemical markers in Alzheimer's disease. Int J Mol Sci 2020; 21(06): 1989

[3] Brouwers N, Sleegers K, Van Broeckhoven C.Molecular genetics of Alzheimer's disease: an update. Ann Med 2008; 40(08): 562-583

[4] Rezazadeh M, Hosseinzadeh H, Moradi M.et al.Genetic discoveries and advances in late-onset Alzheimer's disease. J Cell Physiol 2019; 234(10): 16873-16884

[5] Tanriverdi F, Taheri S, Ulutabanca H.et al.Apolipoprotein E3/E3 genotype decreases the risk of pituitary dysfunction after traumatic brain injury due to various causes: preliminary data. J Neurotrauma 2008; 25(09): 1071-1077

[6] Giri M, Zhang M, Lü Y.Genes associated with Alzheimer's disease: an overview and current status. Clin Interv Aging 2016; 11: 665-681

[7] Gartland KMA, Bruschi F, Dundar M, Gahan PB, Viola Magni Mp, Akbarova Y.Progress towards the ‘Golden Age’ of biotechnology. Curr Opin Biotechnol 2013; 24(Suppl. 01): S6-S13

[8] Bürkle A.Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J 2005; 272(18): 4576-4589

[9] Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays 2004; 26(08): 882-893

[10] Zhou T, Pan F, Cao Y.et al.R152C DNA Pol β mutation impairs base excision repair and induces cellular transformation. Oncotarget 2016; 7(06): 6902-6915

[11] Martins LM, Morrison A, Klupsch K.et al.Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004; 24(22): 9848-9862

[12] Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004; 23(16): 2861-2874

[13] Meeker KD, Meabon JS, Cook DG.Partial loss of the glutamate transporter glt-1 alters brain akt and insulin signaling in a mouse model of Alzheimer's disease. J Alzheimers Dis 2015; 45(02): 509-520

[14] Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen L.HS1-BP3 gene variant is common in familial essential tremor. Mov Disord 2006; 21(03): 306-309

[15] Holland P, Knævelsrud H, Søreng K.et al.HS1BP3 negatively regulates autophagy by modulation of phosphatidic acid levels. Nat Commun 2016; 7: 13889

[16] Yin Z, Klionsky DJ.HS1BP3 provides a novel mechanism of negative autophagy regulation through membrane lipids. Autophagy 2017; 13(05): 779-780

[17] Sato N, Ueki A, Ueno H, Shinjo H, Morita Y.Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type. J Alzheimers Dis 2009; 17(02): 441-448

[18] Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(03): 189-198

[19] Rio DC, Ares Jr. M, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc2010; 2010 (06): prot5439

[20] Talebi M, Delpak A, Khalaj-Kondori M.et al.ABCA7 and EphA1 genes polymorphisms in late-onset Alzheimer's disease. J Mol Neurosci 2020; 70(02): 167-173

[21] Joe E, Ringman JM.Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ 2019; 367: l6217

[22] Shi H, Belbin O, Medway C. et al; Genetic and Environmental Risk for Alzheimer's Disease Consortium, Alzheimer's Research UK Consortium. Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging2012; 33 (08): 1849.e5-1849.e18

[23] Bellenguez C, Grenier-Boley B, Lambert JC.Genetics of Alzheimer's disease: where we are, and where we are going. Curr Opin Neurobiol 2020; 61: 40-48

[24] Li S, Cui Z, Meng X.Knockdown of PARP-1 inhibits proliferation and ERK signals, increasing drug sensitivity in osteosarcoma U2OS cells. Oncol Res 2016; 24(04): 279-286

[25] Langelier MF, Pascal JM.PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 2013; 23(01): 134-143

[26] Li J, Bonkowski MS, Moniot S.et al.A conserved NAD+ binding pocket that regulates protein-protein interactions during aging. Science 2017; 355(6331): 1312-1317

[27] Lillenes MS, Rabano A, Støen M.et al.Altered DNA base excision repair profile in brain tissue and blood in Alzheimer's disease. Mol Brain 2016; 9(01): 61

[28] Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA.Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 2005; 93(04): 953-962

[29] Krishnan KJ, Ratnaike TE, De Gruyter HLM, Jaros E, Turnbull DM.Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. Neurobiol Aging 2012; 33(09): 2210-2214

[30] Canugovi C, Shamanna RA, Croteau DL, Bohr VA.Base excision DNA repair levels in mitochondrial lysates of Alzheimer's disease. Neurobiol Aging 2014; 35(06): 1293-1300

[31] Soltys DT, Pereira CPM, Rowies FT.et al.Lower mitochondrial DNA content but not increased mutagenesis associates with decreased base excision repair activity in brains of AD subjects. Neurobiol Aging 2019; 73: 161-170

[32] Iida T, Furuta A, Nishioka K, Nakabeppu Y, Iwaki T.Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer's disease brain. Acta Neuropathol 2002; 103(01): 20-25

[33] Weissman L, Jo DG, Sørensen MM.et al.Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res 2007; 35(16): 5545-5555

[34] Lovell MA, Xie C, Markesbery WR.Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res 2000; 855(01): 116-123

[35] Sobol RW, Wilson SH.Mammalian DNA β-polymerase in base excision repair of alkylation damage. Prog Nucleic Acid Res Mol Biol 2001; 68: 57-74

[36] Ertuzun T, Semerci A, Cakir ME.et al.Investigation of base excision repair gene variants in late-onset Alzheimer's disease. PLoS One 2019; 14(08): e0221362

[37] Lillenes MS, Støen M, Gómez-Muñoz M.et al.Transient OGG1, APE1, PARP1 and Polβ expression in an Alzheimer's disease mouse model. Mech Ageing Dev 2013; 134(10): 467-477

[38] Misiak M, Vergara Greeno R, Baptiste BA.et al.DNA polymerase β decrement triggers death of olfactory bulb cells and impairs olfaction in a mouse model of Alzheimer's disease. Aging Cell 2017; 16(01): 162-172

[39] Sykora P, Misiak M, Wang Y.et al.DNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypes. Nucleic Acids Res 2015; 43(02): 943-959

[40] Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R.Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ 2004; 11(02): 208-216

[41] van Loo G, van Gurp M, Depuydt B.et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ 2002; 9(01): 20-26

[42] Darreh-Shori T, Rezaeianyazdi S, Lana E.et al.Increased active OMI/HTRA2 serine protease displays a positive correlation with cholinergic alterations in the Alzheimer's disease brain. Mol Neurobiol 2019; 56(07): 4601-4619

[43] Westerlund M, Behbahani H, Gellhaar S.et al.Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's disease. FASEB J 2011; 25(04): 1345-1352

[44] Liu MJ, Liu ML, Shen YF.et al.Transgenic mice with neuron-specific overexpression of HtrA2/Omi suggest a neuroprotective role for HtrA2/Omi. Biochem Biophys Res Commun 2007; 362(02): 295-300

[45] Madeira C, Vargas-Lopes C, Brandão CO.et al.Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer's disease and depression. Front Psychiatry 2018; 9(NOV): 561

[46] Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR. Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol Aging2011; 32 (03): 553.e1-553.e11

[47] Mitani A, Tanaka K.Functional changes of glial glutamate transporter GLT-1 during ischemia: an in vivo study in the hippocampal CA1 of normal mice and mutant mice lacking GLT-1. J Neurosci 2003; 23(18): 7176-7182

[48] Nixon RA.The role of autophagy in neurodegenerative disease. Nat Med 2013; 19(08): 983-997

[49] Montoya A, Elgueta D, Campos J.et al.Dopamine receptor D3 signalling in astrocytes promotes neuroinflammation. J Neuroinflammation 2019; 16(01): 258

[50] Schwartz JC, Diaz J, Pilon C, Sokoloff P.Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 2000; 31(2-3): 277-287

[51] Kandemir N, Gultekin M, Kara M.et al.Propranolol decreases DRD3 and SLC1A2 gene expression in patients with essential tremor. Universa Med 2020; 39(02): 105-112

RIGHTS & PERMISSIONS

2022 Global Medical Genetics